Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDIAC: IFX-1 dose-escalation in complex cardiac surgery
2015-003036-12Phase 2Completed
- Sponsor
- InflaRx
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilobelimab in Systemic Inflammatory Response Syndrome (SIRS) and organ dysfunction (5 arms), sponsored by InflaRx. Primary endpoint: Peak IL-6 level. Started Oct 2015; status: completed.
02
Drugs
vilobelimab
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)organ dysfunction
Beyond the preview
Go deeper on 2015-003036-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003036-12.